Abstract. We experienced a case of fetal goitrous hypothyroidism in an infant delivered by a 33-year-old woman receiving 300 mg/day of propylthiouracil (PTU) for hyperthyroidism due to Graves' disease. A large fetal goiter (maximum diameter, 60 mm) was detected by magnetic resonance imaging (MRI) at 36 weeks of gestation. Initial fetal blood sampling revealed hypothyroidism with a serum thyroid-stimulating hormone (TSH) of 99 µIU/mL, free triiodothyronine (T 3 ) of 1.97 pg/mL, and free thyroxine (T 4 ) of 0.29 ng/dL. Consequently, a diagnosis of fetal goitrous hypothyroidism due to transplacental passage of maternal PTU was made. To reduce the risk of perinatal complications, 300 µg of levothyroxine sodium (L-T 4 ) was administered into the maternal amniotic fluid twice between 37 and 38 weeks of gestation. Subsequent fetal MRI showed that the size of goiter had decreased. At 38 weeks and 5 days of gestation, a 3042-g male infant was born by cesarean section. There were no severe complications at delivery, although mild tachypnea was observed and the infant's thyroid gland was slightly enlarged. He was treated with L-T 4 for two weeks. At present, his growth and neurological development are normal. This case indicates that intrauterine therapy by the intraamniotic administration of L-T 4 can be effective in treating fetal goitrous hypothyroidism even during late gestation.
FETAL goitrous hypothyroidism is a rare but potentially dangerous disease. A large goiter may cause hyperextension of the neck of the fetus, resulting in malpresentation and dystocia [1] . Additionally, in the neonate, the goiter can obstruct the trachea and esophagus, which may cause asphyxia and death at delivery [2] . Untreated intrauterine hypothyroidism may also result in motor or cognitive deficits, or impaired intellectual development [3] [4] [5] . Therefore, early intrauterine diagnosis and adequate treatment are essential. We report a case of fetal goitrous hypothyroidism caused by the transplacental passage of maternal propylthiouracil (PTU). In this case, we diagnosed fetal goitrous hypothyroidism in utero by magnetic resonance imaging (MRI) and fetal blood sampling. Furthermore, we successfully treated the condition with the intraamniotic administration of levothyroxine sodium (L-T 4 ) given as late as at 37 weeks of gestation.
Case Report
A 33-year-old pregnant woman with hyperthyroidism due to Graves' disease was referred to our university hospital at 36 weeks and 4 days of gestation because a large fetal neck mass had been found by ultrasonography. The diagnosis of Graves' disease had been made two years earlier, and she was treated with 300 mg/day of PTU during pregnancy. Her recent serum levels of thyroid-stimulating hormone (TSH) and thyroxine (T 4 ) were 1.4 µIU/mL and 9.8 µg/dL, respectively. At 36 weeks and 5 days of gestation, a goiter whose maxi-mum diameter was 60 mm was detected by fetal MRI (Fig. 1A) . However, no tracheal compression of the fetus or polyhydramniosis was observed. Fetal blood sampling revealed serum levels of TSH, free T 3 and free T 4 of 99 µIU/mL, 1.97 pg/mL and 0.29 ng/dL, respectively. These findings were most consistent with a diagnosis of fetal goitrous hypothyroidism caused by the transplacental passage of maternal PTU. To reduce the risk of perinatal complications, 300 µg of L-T 4 was administered into the maternal amniotic fluid at 37 weeks and 4 days of gestation. This therapy was approved by the local ethics committee of Jikei University School of Medicine. As shown in Figure 1B , subsequent fetal MRI demonstrated slight shrinkage of the goiter (maximum diameter, 50 mm) at 38 weeks and 2 days of gestation. Nevertheless, fetal blood sampling at that time revealed a TSH level that was still elevated at 105 µIU/mL, and a second dose of 300 µg of L-T 4 was administered intraamniotically. The patient was delivered by cesarean section at 38 weeks and 5 days of gestation in order to prevent the obstetric complications associated with the fetal goiter. The male infant weighed 3042 g and his Apgar scores were 8 at 1 min and 9 at 5 min. On physical examination, mild tachypnea and retraction were found; a slightly enlarged thyroid (maximum diameter, 40 mm) was also present (Fig. 2) . The patient's laboratory findings were as follows: hemoglobin, 16.0 g/dL; sodium, 142 mmol/L; potassium, 3.9 mmol/L; chloride, 113 mmol/L; blood urea nitrogen (BUN), 9 mg/dL; C-reactive protein (CRP), 0.29 mg/dL; blood pH, 7.349; pCO2, 33.0 mmHg; pO2, 107.8 mmHg; bicarbonate, 17.8 mmol/L; and base excess, -6.7 mmol/L. Endocrinological findings revealed serum levels of TSH, free T 3 and free T 4 of 32.96 µIU/mL, 2.31 pg/mL and 1.40 ng/dL, respectively (Table 1) . Thyroid stimulating antibody (TSAb) was 88% (normal: <180%). Thyroglobulin antibody (TGAb) and thyroid peroxidase antibody (TPOAb) were 3.2 IU/mL and 5.1 IU/mL, respectively (normal: <0.3 IU/mL). A knee X-ray demonstrated hypoplasia of the distal femoral epiphyseal center (the width and length: 2 mm × 1 mm). On the day of delivery, the patient was treated with oxygen and intravenous drip infusion. Oxygen was discontinued on day 9. Additionally, oral administration of L-T 4 at a dose of 10 µg/ kg/day was started on day 2 for persistent neonatal hypothyroidism. The dose was decreased to 5 µg/kg/day on day 7, since the patient's thyroid function had normalized. L-T 4 therapy was discontinued on day 14, at which point his goiter had already disappeared. On day 27, he was discharged without medication. At present, the patient's growth and neurological development are normal.
Discussion
Fetal goitrous hypothyroidism is an uncommon condition reported to be associated with intrauterine exposure to goitrogens, congenital metabolic disorders of the thyroid system, and chronic iodine deficiency [6] [7] [8] . The class of goitrogens includes antithyroid drugs, iodine-containing vitamins, and iodine-rich products [9] . Graves' disease is common among young women, and is seen in about 0.2% of pregnant women [10] . Pregnant women with Graves' disease are usually treated with an antithyroid drug such as PTU; however, large doses of PTU can affect the fetus, causing hypothyroidism and goiter, because PTU passes through the placenta. Indeed, maternal treatment for hyperthyroidism has been reported to contribute to the development of fetal goitrous hypothyroidism [11] . Noninvasive management of maternal hyperthyroidism is essentially recommended for fetuses with goiter caused by maternal antithyroid drug. According to recent reports, some cases with fetal goiter were initially managed by dose reduction or discontinuation of the maternal PTU [12, 13] . Cohen et al. described that in utero ultrasonography of the fetal thyroid gland is an effective noninvasive tool for monitoring drug dosage in patients receiving antithyroid treatment for Graves' disease in pregnancy [14] . It can lead to the early detection of fetal goitrous hypothyroidism, and dose reduction may prevent adverse hypothyroid-induced effects on psychomotor development and goiter-associated problems at delivery. Therefore, it is important to evaluate fetal goiter and thyroid function at regular intervals in cases of maternal hyperthyroidism such as those caused by Graves' disease and treated with PTU.
On the other hand, in some patients with Graves' disease for whom dose reduction of antithyroid drug is impossible during pregnancy, intrauterine treatment should be considered once fetal goitrous hypothyroidism is confirmed. The first intrauterine treatment of fetal goitrous hypothyroidism due to the transplacental passage of maternal PTU was successfully performed in 1980 by injecting L-T 4 into the amniotic fluid [11] . To date, 8 similar cases, including the present case, have been reported in the English literature [2, [15] [16] [17] [18] . Intrauterine L-T 4 therapy was considered to be effective for both the fetal goiter and the hypothyroidism in all reported cases.
In the present case, intrauterine L-T 4 therapy was successfully conducted twice although the diagnosis of fetal goitrous hypothyoidism was determined at a late gestational age. Because the patient's TSAb was negative at birth and his mother was euthyroid during pregnancy, dose reduction of maternal PTU at an appropriate gestational age might have prevented fetal goiter and hypothyroidism. However, the patient's mother was treated with large dose of PTU, and referred to our hospital because of a large fetal neck mass at 36 weeks of gestation. After admission, fetal MRI and blood sampling were useful for us in the diagnosis of fetal goitrous hypothyroidism and to evaluate the effect of the intrauterine treatment. Reynolds et al. recently noted in their review that fetal MRI was more valuable than ultrasonography in the diagnosis and follow-up of fetal goiter [19] . Additionally, Agrawal et al. point out the significance of initial fetal diagnosis using fetal blood sampling because direct quantification of fetal thyroid hormones allows an accurate determination of the fetal thyroid state [20] . It is important to note that the measurement of amniotic fluid TSH levels using amniocentesis has proven to be unreliable in predicting fetal thyroid status [21, 22] . Therefore, [17] . The present case was treated with the intraamniotic administration of L-T 4 each week at a dose of 15 µg/kg/day for severe congenital hypothyroidism. On the other hand, Gruner et al. tried five weekly doses of 250 µg L-T 4 from 26 weeks of gestation in a case with fetal goitrous hypothyroidism caused by defect in thyroid hormone synthesis. Furthermore, the dosage was increased to 500 µg in the subsequent five injections because of the persistent goiter and the elevated TSH in the cord blood [23] . To determine the appropriate dose of L-T 4 and interval of administration, sufficient pharmacokinetic data of human fetal uptake and absorption of L-T 4 from the amniotic fluid will be necessary. However, the effective dose of L-T 4 seems to be influenced by pathogenic basis of fetal goitrous hypothyroidism.
The critical gestational age for the initiation of therapy also remains unclear. It must be determined clinically by balancing the risks of not treating the condition against the risk of prematurity at that age of gestation. Van Herle et al. recommended the intraamniotic injection of L-T 4 beginning at 32 weeks of gestation [24] , while Sagot et al. suggested the intrauterine treatment of thyroid goiters at late ages of gestation up to 36 weeks [25] . Regarding fetal goitrous hypothyroidism due to maternal PTU, intrauterine therapy was initiated between 25 and 35 weeks of gestation [2, [15] [16] [17] [18] . In the present case, the diagnosis made late at 36 weeks of gestation. Since neither tracheal compression nor polyhydramniosis was found, intraamniotic injection of L-T 4 was started at 37 weeks and 4 days of gestation. This delayed approach nevertheless brought about slight shrinkage of the goiter and improvement of fetal thyroid function and there were no severe complications at birth. Although we successfully managed the condition of the present case, further study will be required to define the optimal gestational age at which to start therapy for fetal goitrous hypothyroidism.
In conclusion, our case indicates that intrauterine therapy by the intraamniotic administration of L-T 4 can be effective for fetal goitrous hypothyroidism even at a late age of gestation. Long-term evaluation of the patient's prognosis for growth and neurological development will confirm the effects of this prenatal treatment.
